::: {.grid}

::: {.g-col-4}
![](./img/dna.png){fig-alt="DNA strand" .img-fluid}
:::

::: {.g-col-8}
### OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company {.mt-0}

OSR Holdings, Inc. (NASDAQ: OSRH) announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2.

::: {.text-center}
[Read more](https://osr-holdings.com/news/?q=YToxOntzOjEyOiJrZXl3b3JkX3R5cGUiO3M6MzoiYWxsIjt9&bmode=view&idx=166816633&t=board){.btn .btn-outline-primary}
:::
:::

::: {.g-col-4}
![](./img/newswire.png){fig-alt="PR Newswire logo" .img-fluid}
:::

::: {.g-col-8}
### Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma {.mt-0}

Vaximm AG, a subsidiary of OSR Holdings, Inc., announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01 in combination with PD-L1 inhibitor in patients with recurrent glioblastoma.

::: {.text-center}
[Read more](https://osr-holdings.com/news/?q=YToyOntzOjEyOiJrZXl3b3JkX3R5cGUiO3M6MzoiYWxsIjtzOjQ6InBhZ2UiO2k6Mjt9&bmode=view&idx=159644069&t=board){.btn .btn-outline-primary}
:::
:::

:::